| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0000084 | Mitotic s phase | Increases phenotype | PMID:30467747; PMID:32530119 |
| GO:0000086 | G2/m transition of mitotic cell cycle | Decreases phenotype | PMID:30467747; PMID:30467747; PMID:32530119; PMID:32530119 |
| GO:0000165 | Mapk cascade | Increases phenotype | PMID:14645110 |
| GO:0000278 | Mitotic cell cycle | Decreases phenotype | PMID:10785588; PMID:30467747; PMID:30664189 |
| GO:0001552 | Ovarian follicle atresia | Increases phenotype | PMID:27395752 |
| GO:0001553 | Luteinization | Decreases phenotype | PMID:27395752; PMID:28248286 |
| GO:0002027 | Regulation of heart rate | Affects phenotype | PMID:29571322 |
| GO:0002523 | Leukocyte migration involved in inflammatory response | Increases phenotype | PMID:29571322; PMID:29974145 |
| GO:0004364 | Glutathione transferase activity | Increases phenotype | PMID:38779996 |
| GO:0004457 | Lactate dehydrogenase activity | Increases phenotype | PMID:38779996 |
| GO:0004510 | Tryptophan 5-monooxygenase activity | Affects phenotype | PMID:28463726 |
| GO:0005262 | Calcium channel activity | Affects phenotype | PMID:24205315 |
| GO:0006094 | Gluconeogenesis | Decreases phenotype | PMID:21570382 |
| GO:0006096 | Glycolytic process | Affects phenotype | PMID:1525059; PMID:21570382 |
| GO:0006106 | Fumarate metabolic process | Affects phenotype | PMID:29974145 |
| GO:0006304 | Dna modification | Increases phenotype | PMID:25123088 |
| GO:0006306 | Dna methylation | Decreases phenotype | PMID:17219426 |
| GO:0006606 | Protein import into nucleus | Affects phenotype | PMID:26470790 |
| GO:0006641 | Triglyceride metabolic process | Affects phenotype | PMID:38191086 |
| GO:0006646 | Phosphatidylethanolamine biosynthetic process | Affects phenotype | PMID:28138993 |
| GO:0006656 | Phosphatidylcholine biosynthetic process | Decreases phenotype | PMID:28138993 |
| GO:0006661 | Phosphatidylinositol biosynthetic process | Increases phenotype | PMID:28138993 |
| GO:0006749 | Glutathione metabolic process | Affects phenotype | PMID:29183790; PMID:32530119 |
| GO:0006805 | Xenobiotic metabolic process | Increases phenotype | PMID:29162470 |
| GO:0006809 | Nitric oxide biosynthetic process | Increases phenotype | PMID:31416231 |
| GO:0006811 | Monoatomic ion transport | Increases phenotype | PMID:10991979 |
| GO:0006884 | Cell volume homeostasis | Increases phenotype | PMID:22108225 |
| GO:0006914 | Autophagy | Affects phenotype | PMID:11872957; PMID:18172760; PMID:18172760; PMID:21233418; PMID:20594311 |
| GO:0006915 | Apoptotic process | Increases phenotype | PMID:10771088; PMID:10785588; PMID:11356682; PMID:11485825; PMID:12169386; PMID:12602925; PMID:12611458; PMID:12611458; PMID:12721755; PMID:17011908; PMID:17767197; PMID:18172760; PMID:18815881; PMID:21233418; PMID:12721755; PMID:12747936; PMID:12810152; PMID:14649542; PMID:14990993; PMID:15604281; PMID:15604281; PMID:9329022; PMID:15606891; PMID:15748701; PMID:16497877; PMID:17011908; PMID:17186241; PMID:17767197; PMID:18172760; PMID:18790785; PMID:18815881; PMID:19931998; PMID:20594311; PMID:21413024; PMID:23840623; PMID:25301941; PMID:30153467; PMID:30467747; PMID:30980508; PMID:32530119; PMID:38779996; PMID:39561883; PMID:27163517; PMID:30153467; PMID:30467747; PMID:30980508; PMID:32530119; PMID:34463000; PMID:39561883; PMID:9742967; PMID:9888466 |
| GO:0006936 | Muscle contraction | Increases phenotype | PMID:28138957 |
| GO:0006974 | Cellular response to dna damage stimulus | Increases phenotype | PMID:30153467 |
| GO:0006979 | Response to oxidative stress | Increases phenotype | PMID:31532279; PMID:9888466 |
| GO:0007049 | Cell cycle | Increases phenotype | PMID:11485825; PMID:12602925; PMID:14645110; PMID:15665275; PMID:16450001; PMID:17186241; PMID:17767197; PMID:17876043; PMID:20225760; PMID:7753712 |
| GO:0007283 | Spermatogenesis | Increases phenotype | PMID:34974146; PMID:8070710 |
| GO:0007565 | Female pregnancy | Decreases phenotype | PMID:28248286 |
| GO:0007585 | Respiratory gaseous exchange by respiratory system | Decreases phenotype | PMID:29571322 |
| GO:0007613 | Memory | Decreases phenotype | PMID:24902786; PMID:37392961 |
| GO:0007614 | Short-term memory | Decreases phenotype | PMID:24902786 |
| GO:0007616 | Long-term memory | Decreases phenotype | PMID:24902786 |
| GO:0008219 | Cell death | Increases phenotype | PMID:10715583; PMID:11034078; PMID:12632256; PMID:12894523; PMID:14645110; PMID:15190103; PMID:16450001; PMID:16497877; PMID:18167132; PMID:19330798; PMID:28322778; PMID:7753712 |
| GO:0008283 | Cell population proliferation | Increases phenotype | PMID:10505046; PMID:11485825; PMID:11735166; PMID:12169386; PMID:12602925; PMID:12611458; PMID:17186241; PMID:17876043; PMID:20225760; PMID:2386944; PMID:2846159; PMID:3458212; PMID:6542011; PMID:12632256; PMID:12894523; PMID:1333883; PMID:15642790; PMID:15665275; PMID:15750629; PMID:16263272; PMID:1661414; PMID:1661414; PMID:21513275; PMID:17186241; PMID:17219426; PMID:17458902; PMID:24213142; PMID:30664189; PMID:17572228; PMID:17876043; PMID:18066117; PMID:18066117; PMID:6542011; PMID:8110496; PMID:18575591; PMID:18575591; PMID:21513275; PMID:9714066; PMID:19031437; PMID:19549922; PMID:19874578; PMID:20225760; PMID:20302909; PMID:20535544; PMID:21413024; PMID:21513275; PMID:21513275; PMID:24758408; PMID:25301941; PMID:22138011; PMID:28763032; PMID:23786776; PMID:2386944; PMID:24758408; PMID:25301941; PMID:27163517; PMID:2936615; PMID:30664189; PMID:3458212; PMID:7588234; PMID:7923186; PMID:8110496; PMID:9888466 |
| GO:0008284 | Positive regulation of cell population proliferation | Affects phenotype | PMID:22108225; PMID:28811679; PMID:32171938; PMID:34270681; PMID:34821461; PMID:9224209 |
| GO:0008285 | Negative regulation of cell population proliferation | Increases phenotype | PMID:21687957; PMID:22037685; PMID:23159075; PMID:32497533; PMID:34821461 |
| GO:0008584 | Male gonad development | Decreases phenotype | PMID:23213263 |
| GO:0008585 | Female gonad development | Decreases phenotype | PMID:28248286 |
| GO:0008610 | Lipid biosynthetic process | Increases phenotype | PMID:27089845 |
| GO:0008654 | Phospholipid biosynthetic process | Affects phenotype | PMID:28138993; PMID:28552552 |
| GO:0009086 | Methionine biosynthetic process | Affects phenotype | PMID:29974145 |
| GO:0010694 | Positive regulation of alkaline phosphatase activity | Increases phenotype | PMID:27159630 |
| GO:0010729 | Positive regulation of hydrogen peroxide biosynthetic process | Increases phenotype | PMID:15545282 |
| GO:0010825 | Positive regulation of centrosome duplication | Increases phenotype | PMID:27998958 |
| GO:0010918 | Positive regulation of mitochondrial membrane potential | Increases phenotype | PMID:15545282 |
| GO:0010942 | Positive regulation of cell death | Increases phenotype | PMID:15545282; PMID:23397584 |
| GO:0014734 | Skeletal muscle hypertrophy | Increases phenotype | PMID:29571322 |
| GO:0016049 | Cell growth | Decreases phenotype | PMID:30153467 |
| GO:0019249 | Lactate biosynthetic process | Decreases phenotype | PMID:29974145 |
| GO:0019432 | Triglyceride biosynthetic process | Decreases phenotype | PMID:28138993 |
| GO:0019722 | Calcium-mediated signaling | Increases phenotype | PMID:11034078; PMID:11034078; PMID:15604281; PMID:11034078; PMID:17011908; PMID:12632256; PMID:17011908; PMID:21413024 |
| GO:0019853 | L-ascorbic acid biosynthetic process | Decreases phenotype | PMID:29974145 |
| GO:0022832 | Voltage-gated channel activity | Affects phenotype | PMID:33512997 |
| GO:0030199 | Collagen fibril organization | Increases phenotype | PMID:29571322 |
| GO:0030282 | Bone mineralization | Decreases phenotype | PMID:29571322 |
| GO:0030335 | Positive regulation of cell migration | Increases phenotype | PMID:34821461 |
| GO:0030336 | Negative regulation of cell migration | Increases phenotype | PMID:34270681; PMID:34821461 |
| GO:0030520 | Intracellular estrogen receptor signaling pathway | Increases phenotype | PMID:36513145 |
| GO:0031324 | Negative regulation of cellular metabolic process | Increases phenotype | PMID:29445054 |
| GO:0032049 | Cardiolipin biosynthetic process | Increases phenotype | PMID:28138993 |
| GO:0032148 | Activation of protein kinase b activity | Increases phenotype | PMID:34821461 |
| GO:0032735 | Positive regulation of interleukin-12 production | Increases phenotype | PMID:28811679 |
| GO:0032792 | Negative regulation of creb transcription factor activity | Increases phenotype | PMID:37392961 |
| GO:0032930 | Positive regulation of superoxide anion generation | Increases phenotype | PMID:15545282 |
| GO:0034383 | Low-density lipoprotein particle clearance | Affects phenotype | PMID:27358406 |
| GO:0034440 | Lipid oxidation | Increases phenotype | PMID:29183790; PMID:38779996 |
| GO:0035847 | Uterine epithelium development | Increases phenotype | PMID:24487097 |
| GO:0036164 | Cell-abiotic substrate adhesion | Decreases phenotype | PMID:33024228 |
| GO:0040011 | Locomotion | Affects phenotype | PMID:29571322 |
| GO:0040015 | Negative regulation of multicellular organism growth | Increases phenotype | PMID:30672060 |
| GO:0042307 | Positive regulation of protein import into nucleus | Increases phenotype | PMID:27358406 |
| GO:0042311 | Vasodilation | Increases phenotype | PMID:21092740 |
| GO:0042412 | Taurine biosynthetic process | Decreases phenotype | PMID:29974145 |
| GO:0042420 | Dopamine catabolic process | Affects phenotype | PMID:28463726 |
| GO:0042422 | Norepinephrine catabolic process | Affects phenotype | PMID:28463726 |
| GO:0042429 | Serotonin catabolic process | Affects phenotype | PMID:28463726 |
| GO:0042554 | Superoxide anion generation | Increases phenotype | PMID:12628514 |
| GO:0042755 | Eating behavior | Affects phenotype | PMID:38191086 |
| GO:0043065 | Positive regulation of apoptotic process | Increases phenotype | PMID:21413024; PMID:22646800; PMID:34821461; PMID:35468944 |
| GO:0043066 | Negative regulation of apoptotic process | Increases phenotype | PMID:34821461 |
| GO:0044237 | Cellular metabolic process | Increases phenotype | PMID:15149724; PMID:15196704; PMID:30467747; PMID:30980508; PMID:31576639; PMID:32530119; PMID:39561883; PMID:22905168; PMID:29940172; PMID:30467747; PMID:30980508; PMID:31576639; PMID:32530119; PMID:34463000; PMID:39561883 |
| GO:0044319 | Wound healing, spreading of cells | Decreases phenotype | PMID:30153467; PMID:32530119; PMID:32530119 |
| GO:0044849 | Estrous cycle | Decreases phenotype | PMID:27395752 |
| GO:0045023 | G0 to g1 transition | Affects phenotype | PMID:30467747; PMID:30467747; PMID:30980508; PMID:32530119; PMID:30980508; PMID:32530119 |
| GO:0045429 | Positive regulation of nitric oxide biosynthetic process | Increases phenotype | PMID:15545282 |
| GO:0045795 | Positive regulation of cell volume | Increases phenotype | PMID:21792908; PMID:22108225; PMID:22108225 |
| GO:0045930 | Negative regulation of mitotic cell cycle | Increases phenotype | PMID:30153467; PMID:30153467; PMID:30467747; PMID:30980508; PMID:32530119; PMID:30467747; PMID:30467747; PMID:30980508; PMID:32530119; PMID:30467747; PMID:32530119; PMID:30980508; PMID:32530119 |
| GO:0046058 | Camp metabolic process | Affects phenotype | PMID:27936172 |
| GO:0046323 | Glucose import | Affects phenotype | PMID:38779996 |
| GO:0046466 | Membrane lipid catabolic process | Affects phenotype | PMID:17283165; PMID:1884432; PMID:31532279; PMID:8494544 |
| GO:0046620 | Regulation of organ growth | Affects phenotype | PMID:27395752 |
| GO:0046622 | Positive regulation of organ growth | Affects phenotype | PMID:27395752 |
| GO:0046649 | Lymphocyte activation | Decreases phenotype | PMID:19031437 |
| GO:0046716 | Muscle cell cellular homeostasis | Affects phenotype | PMID:29571322 |
| GO:0050729 | Positive regulation of inflammatory response | Increases phenotype | PMID:35468944 |
| GO:0051298 | Centrosome duplication | Increases phenotype | PMID:36384894 |
| GO:0051881 | Regulation of mitochondrial membrane potential | Decreases phenotype | PMID:14990993; PMID:17283165; PMID:20225760; PMID:27089845; PMID:32530119 |
| GO:0051882 | Mitochondrial depolarization | Increases phenotype | PMID:21413024 |
| GO:0051898 | Negative regulation of protein kinase b signaling | Increases phenotype | PMID:37392961 |
| GO:0055119 | Relaxation of cardiac muscle | Affects phenotype | PMID:24205315 |
| GO:0060004 | Reflex | Decreases phenotype | PMID:25595991 |
| GO:0060065 | Uterus development | Decreases phenotype | PMID:28248286 |
| GO:0060326 | Cell chemotaxis | Decreases phenotype | PMID:32530119 |
| GO:0070265 | Necrotic cell death | Increases phenotype | PMID:29571322; PMID:29974145 |
| GO:0070374 | Positive regulation of erk1 and erk2 cascade | Increases phenotype | PMID:27358406 |
| GO:0070782 | Phosphatidylserine exposure on apoptotic cell surface | Increases phenotype | PMID:15545282 |
| GO:0070873 | Regulation of glycogen metabolic process | Affects phenotype | PMID:30672060 |
| GO:0070994 | Detection of oxidative stress | Increases phenotype | PMID:24486436 |
| GO:0071466 | Cellular response to xenobiotic stimulus | Increases phenotype | PMID:32497533 |
| GO:0072593 | Reactive oxygen species metabolic process | Increases phenotype | PMID:32530119; PMID:34463000; PMID:38779996 |
| GO:0086003 | Cardiac muscle cell contraction | Affects phenotype | PMID:24205315 |
| GO:0090327 | Negative regulation of locomotion involved in locomotory behavior | Increases phenotype | PMID:29183790 |
| GO:0097327 | Response to antineoplastic agent | Increases phenotype | PMID:26078298; PMID:32001260 |
| GO:0140042 | Lipid droplet formation | Increases phenotype | PMID:38191086 |
| GO:0140354 | Lipid import into cell | Increases phenotype | PMID:35944649 |
| GO:1900087 | Positive regulation of g1/s transition of mitotic cell cycle | Increases phenotype | PMID:34821461 |
| GO:1901216 | Positive regulation of neuron death | Increases phenotype | PMID:29183790 |
| GO:1902476 | Chloride transmembrane transport | Affects phenotype | PMID:21792908; PMID:22108225; PMID:22108225 |
| GO:1902512 | Positive regulation of apoptotic dna fragmentation | Increases phenotype | PMID:21413024 |
| GO:1902608 | Positive regulation of large conductance calcium-activated potassium channel activity | Increases phenotype | PMID:21413024 |
| GO:1902941 | Regulation of voltage-gated chloride channel activity | Affects phenotype | PMID:33512997 |
| GO:1903047 | Mitotic cell cycle process | Affects phenotype | PMID:38779996 |
| GO:1903409 | Reactive oxygen species biosynthetic process | Increases phenotype | PMID:27089845; PMID:30153467 |
| GO:1903428 | Positive regulation of reactive oxygen species biosynthetic process | Increases phenotype | PMID:34821461 |
| GO:1903709 | Uterine gland development | Affects phenotype | PMID:24487097; PMID:27395752 |
| GO:1903999 | Negative regulation of eating behavior | Increases phenotype | PMID:30672060 |
| GO:1904109 | Positive regulation of cholesterol import | Increases phenotype | PMID:35944649 |
| GO:1905602 | Positive regulation of receptor-mediated endocytosis involved in cholesterol transport | Increases phenotype | PMID:35944649 |
| GO:1905867 | Epididymis development | Affects phenotype | PMID:34974146 |
| GO:2000134 | Negative regulation of g1/s transition of mitotic cell cycle | Increases phenotype | PMID:34821461 |
| GO:2000386 | Positive regulation of ovarian follicle development | Decreases phenotype | PMID:28248286 |
| GO:2001024 | Negative regulation of response to drug | Increases phenotype | PMID:34821461 |
| GO:2001200 | Positive regulation of dendritic cell differentiation | Increases phenotype | PMID:28811679 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.